78 results
6-K
EX-99.1
OBSVF
ObsEva SA
9 May 19
Index to Unaudited Condensed Consolidated Financial Statements
6:05am
, fixtures and equipment
Intangible assets
Other long-term assets
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
Current … liabilities
Non-current lease liabilities
Post-employment obligations
Other long-term liabilities
Total non-current liabilities
Shareholders’ equity
Share
6-K
EX-99.1
OBSVF
ObsEva SA
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
to be presented orally-
-Long-term follow-up data from Phase 2b EDELWEISS study of linzagolix for the treatment of endometriosis demonstrating bone mineral … of hormonal add-back therapy. In the endometriosis indication, the long-term results from the Phase 2b study showing BMD recovery are encouraging. Together
6-K
EX-99.1
OBSVF
ObsEva SA
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
focused on securing further sources of long-term funding as well as suitable commercialization partners. Given the very positive outlook for ObsEva, our … entire team is excited about the coming year and what the long-term future holds.”
Anticipated Milestones
ObsEva aims to achieve the following key
6-K
EX-99.1
OBSVF
ObsEva SA
13 Nov 19
Index to Unaudited Condensed Consolidated Financial Statements
4:00pm
assets
Furniture, fixtures and equipment
Intangible assets
Other long-term assets
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS … liabilities
Non-current liabilities
Non-current lease liabilities
Non-current borrowings
Post-employment obligations
Other long-term liabilities
Total non
6-K
EX-99.2
OBSVF
ObsEva SA
10 Dec 20
Current report (foreign)
6:03am
to 6 months) when rapid reduction in fibroid and uterine volume is desired For long-term use for women with a contraindication to or who prefer … to avoid ABT For long-term use for women for whom ABT is appropriate
ABT = Add Back Therapy (1mg estradiol + 0.5 mg norethindrone acetate) Primary efficacy
6-K
EX-99.1
at2esdg g33m3y
8 Aug 18
Index to Unaudited Consolidated Interim Financial Statements
7:00am
6-K
EX-99.3
7lk061 vv
7 Nov 19
Current report (foreign)
9:11am
6-K
EX-99.3
0why4l4gq
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.3
c8ohuobu dcedqci
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.3
i55 g1wel4
9 May 19
Index to Unaudited Condensed Consolidated Financial Statements
6:05am
6-K
EX-99.1
mia08st511q8u2jy
16 May 18
Index to Unaudited Consolidated Interim Financial Statements
4:56pm
6-K
EX-99.1
vg5 bge481
8 Nov 18
Index to Unaudited Condensed Consolidated Financial Statements
9:28am
6-K
EX-99.1
twa 37mptg6dxqcp
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.3
mraky2d5grux3egg
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
6-K
EX-99.1
i5x97 bjze
7 Aug 19
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
6dlvd5qrtgls vu5
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
9ow3y4thyymo9xa
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
8rhjylik290 4rw4f4y2
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
fyntjgzx7xtqs hz
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.1
wpnci1
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am